April 24, 2011

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial

.   .   

Everolimus is an mTOR inhibitor and does not cause the nephrotoxicity seen with cyclosporine or tacrolimus. Use of mTOR inhibitors as initial immunosuppression at the time of transplant is associated with a higher risk of acute rejection. In this RCT, patients 4.5 months post-transplant were randomized to continue cyclosporine or switch to everolimus. At 12 months, GFR was higher in the everolimus group, despite the patients in this group having experienced more acute rejection episodes.

Related Articles:

Renal Transplantation

Comments are closed.